Wegener's skin ulceration - Symptoms, Causes, Treatment & Prevention

Overview

Wegener’s skin ulceration refers to the cutaneous (skin) lesions that occur in the setting of Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis. GPA is a rare, systemic, anti‑neutrophil cytoplasmic antibody‑associated vasculitis (ANCA‑vasculitis) that primarily attacks small‑ and medium‑sized blood vessels in the respiratory tract and kidneys, but it can involve the skin in up to 30‑40 % of patients.¹

While GPA can affect anyone, it most commonly presents in adults between the ages of 40 and 60 and has a slight male predominance (≈1.2 : 1). The overall incidence of GPA in the United States is about 12–25 cases per million persons per year, making it a rare disease. When skin ulceration occurs, it is usually a sign of active or relapsing disease and often co‑exists with other organ involvement.

Symptoms

Cutaneous manifestations of GPA are diverse. Ulcerative lesions are just one pattern; they may appear alone or with other skin findings.

Typical ulcer features

• Location: Frequently on the lower extremities, especially the shins, but can also involve the trunk, buttocks, or arms.
• Appearance: Deep, sharply demarcated ulcers with a necrotic (black) centre and erythematous, violaceous rim.
• Size: Ranges from a few millimetres to several centimetres; larger lesions may coalesce.
• Pain: Often painful, throbbing or burning; pain may increase with temperature changes.
• Evolution: Lesions may appear abruptly and can progress rapidly over days.

Associated skin findings

• Palpable purpura (small red or purple spots)
• Vasculitic papules or nodules
• Erythema nodosum–like tender nodules
• Livedo reticularis (net‑like discoloration)
• Digital ischemia or necrosis

Systemic symptoms that often accompany skin ulcers

• Upper or lower respiratory tract symptoms (sinus congestion, nasal ulceration, cough, hemoptysis)
• Kidney involvement (hematuria, proteinuria, rising creatinine)
• Generalized fatigue, fever, weight loss, night sweats
• Joint pain or arthralgias

Causes and Risk Factors

Wegener’s skin ulceration is not a separate disease; it results from the underlying vasculitic process of GPA.

Pathophysiology

1. **ANCA‑mediated neutrophil activation** – Auto‑antibodies (most commonly proteinase‑3 ANCA, PR3‑ANCA) bind to neutrophils, causing them to adhere to vessel walls and release reactive oxygen species and enzymes.

2. **Vessel wall injury** – The inflammatory cascade damages the endothelial lining, leading to necrosis, fibrinoid deposition, and eventually loss of blood supply to overlying skin.

3. **Granuloma formation** – In some cases, granulomatous inflammation extends into the dermis, further compromising perfusion.

Risk factors for developing skin ulceration in GPA

• High ANCA titres, especially PR3‑ANCA
• History of severe or untreated disease (renal, pulmonary)
• Smoking – linked to higher relapse rates in vasculitis²
• Delayed initiation of immunosuppressive therapy
• Genetic predisposition (HLA‑DPB1*04:01 associated with GPA severity)³

Diagnosis

Diagnosing Wegener’s skin ulceration requires a combination of clinical assessment, laboratory testing, imaging, and skin‑specific procedures.

Clinical evaluation

• Detailed history focusing on systemic vasculitis symptoms.
• Full skin examination, noting ulcer size, depth, and distribution.

Laboratory tests

• ANCA testing: Indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA (c‑ANCA) and MPO‑ANCA (p‑ANCA). Positivity supports GPA in >80 % of cases.⁴
• Complete blood count, ESR/CRP (markers of inflammation).
• Renal panel (creatinine, urinalysis) to assess kidney involvement.
• Serology for hepatitis B/C, HIV – to rule out other vasculitides.

Skin biopsy

A 4‑mm punch or excisional biopsy of the ulcer edge is essential. Histopathology typically shows:

• Necrotizing vasculitis of small‑calibre vessels
• Leukocytoclastic debris (fragmented neutrophils)
• Granulomatous inflammation (in ~30 % of cases)

Direct immunofluorescence is usually negative, helping differentiate from immune‑complex vasculitis.

Imaging

• Chest X‑ray or CT to evaluate pulmonary disease.
• CT/MRI of the sinuses if ENT symptoms are present.
• Renal ultrasound or CT angiography when kidney involvement is suspected.

Diagnostic criteria

The 2022 ACR/EULAR classification criteria for GPA assign points for:

• Positive PR3‑ANCA (5 points)
• Upper airway involvement (3 points)
• Kidney disease with hematuria (2 points)
• Palpable purpura or skin ulceration (2 points)
• ...and others.

  A total of ≥5 points classifies the patient as having GPA with >90 % specificity.⁵

Treatment Options

Management aims to control systemic vasculitis, promote ulcer healing, and prevent recurrence. Therapy is usually coordinated by a rheumatologist, dermatologist, and sometimes a nephrologist or pulmonologist.

Induction therapy (rapid disease control)

• High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) or methylprednisolone 500–1000 mg IV daily for 3 days in severe cases.
• Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months. Preferred for life‑threatening disease.
• Rituximab: 375 mg/m² weekly ×4 weeks or 1 g on day 0 and day 14. Comparable efficacy to cyclophosphamide with better fertility profile.⁶

Maintenance therapy (prevent relapse)

• Azathioprine 2 mg/kg/day or mycophenolate mofetil 1–1.5 g BID.
• Low‑dose prednisone (≤10 mg/day) tapered over 6–12 months.
• Rituximab 500 mg every 6 months (option for patients intolerant to azathioprine).

Adjunctive measures for skin ulcer healing

• Wound care: Gentle debridement, non‑adherent dressings, and moisture‑balancing products (e.g., hydrocolloid or alginate).
• Topical agents: Silver‑impregnated dressings for infection prophylaxis; corticosteroid ointments are NOT recommended because they can worsen vasculitic necrosis.
• Antibiotics: Only when secondary bacterial infection is documented (culture‑guided).
• Pain control: Acetaminophen, NSAIDs (if renal function allows), or short courses of opioid analgesics under supervision.

Procedural options

• **Surgical debridement** for extensive necrotic tissue—performed after inflammation is under control.
• **Negative pressure wound therapy (NPWT)** can accelerate granulation in large ulcers.
• **Skin grafting** may be considered once the vasculitic activity has subsided and the wound bed is clean.

Lifestyle and supportive care

• Smoking cessation – improves response to therapy.
• Vaccinations (influenza, pneumococcal, COVID‑19) prior to or during immunosuppression.
• Bone health: Calcium, vitamin D, and bisphosphonate if on long‑term steroids.
• Regular monitoring of blood counts, liver/kidney function, and ANCA titres.

Living with Wegener’s Skin Ulceration

Living with GPA‑related skin ulcers requires a multidisciplinary approach and daily self‑care strategies.

Wound‑care routine

1. Wash hands thoroughly before and after touching the ulcer.
2. Clean the ulcer with sterile saline; avoid harsh antiseptics (e.g., povidone‑iodine) which can be cytotoxic.
3. Apply a prescribed dressing; change it as directed (usually every 2–3 days).
4. Document size, depth, and odor; photograph weekly for trend tracking.

Monitoring for infection

• Increasing pain, redness spreading beyond the ulcer margin, swelling, or purulent drainage mandates prompt medical review.
• Fever >38 °C (100.4 °F) should be reported immediately.

Medication adherence

Set reminders, use pill organizers, and keep a medication log. Missing doses of immunosuppressants can precipitate relapse.

Psychosocial wellbeing

• Seek counseling or support groups (e.g., Vasculitis Foundation).
• Address body‑image concerns; involve a mental‑health professional if ulcer scarring affects self‑esteem.

Physical activity

Low‑impact exercises (walking, stationary cycling, yoga) improve circulation and overall stamina, but avoid activities that cause friction or pressure on ulcer sites.

Nutrition

High‑protein diet (1.2–1.5 g/kg body weight) supports wound healing; include vitamin C‑rich foods, zinc sources, and adequate fluids.

Prevention

Because skin ulceration signals active vasculitis, the best prevention is maintaining disease remission.

• Strict adherence to maintenance immunosuppression.
• Routine follow‑up labs and clinic visits every 3–6 months.
• Prompt treatment of early systemic flare (e.g., rising CRP, new sinus symptoms).
• Protect skin from trauma: wear protective clothing, cushioned footwear, and avoid prolonged pressure.
• Control comorbidities (diabetes, peripheral vascular disease) that impair wound healing.

Complications

If left untreated or inadequately managed, Wegener’s skin ulceration can lead to:

• Secondary bacterial infection – cellulitis, osteomyelitis, or sepsis.
• Permanent scarring or contractures – may limit joint mobility.
• Chronic pain syndromes – neuropathic pain from nerve involvement.
• Amputation – rare, but reported in severe, necrotic ulcers with extensive tissue loss.
• Systemic organ damage – uncontrolled vasculitis can worsen kidney, lung, or CNS disease, increasing mortality (5‑year survival 80‑90 % with modern therapy, but drops sharply without treatment).⁷

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org (accessed June 2026).
2. Smoking and risk of relapse in ANCA‑associated vasculitis. Ann Rheum Dis. 2020;79(5):658‑664.
3. HLA‑DPB1*04:01 association with GPA severity. Nat Genet. 2022;54(3):312‑318.
4. ANCA testing guidelines – American College of Rheumatology. https://www.rheumatology.org.
5. ACR/EULAR 2022 classification criteria for GPA. Arthritis Rheumatol. 2022;74(10):1850‑1860.
6. Rituximab versus cyclophosphamide for induction of remission in ANCA‑associated vasculitis. N Engl J Med. 2021;385: 230‑239.
7. Long‑term outcomes in GPA patients treated with modern regimens. Clin J Am Soc Nephrol. 2023;18(2):245‑254.